Loading...
XNAS
PRTA
Market cap595mUSD
Dec 05, Last price  
11.07USD
1D
-0.81%
1Q
29.47%
Jan 2017
-77.50%
IPO
62.79%
Name

Prothena Corporation PLC

Chart & Performance

D1W1MN
XNAS:PRTA chart
P/E
—
P/S
4.41
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.16%
Rev. gr., 5y
178.00%
Revenues
135m
+47.92%
1,243,000507,0002,658,000676,00050,854,0001,607,0001,055,00027,519,000955,000814,000853,000200,577,00053,905,00091,370,000135,157,000
Net income
-122m
L-16.81%
-12,482,000-29,670,000-41,411,000-40,996,000-7,150,000-80,612,000-160,108,000-153,237,000-155,645,000-77,677,000-111,144,00066,975,000-116,949,000-147,028,000-122,310,000
CFO
-150m
L+12.06%
-9,083,000-19,697,000-42,072,000-32,098,000-683,000-62,455,000-117,269,000-131,183,000-28,276,000-52,969,000-80,362,00092,605,000-108,821,000-133,906,000-150,050,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
URL
https://www.prothena.com/
IPO date
Dec 21, 2012
Employees
127
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT